Critical IllnessIntensive Care PatientsCritical Illness Requiring Intensive Care - SepsisCritical Illness Requiring Intensive Care - Acute Brain InjuryCritical Illness Requiring Intensive Care - Major SurgeryCritical Illness Requiring Intensive Care - Polytrauma
Study summary
This is a prospective observational physiopathological study aimed at evaluating the immunological and inflammatory determinants associated with the prognosis of patients admitted to intensive care units (ICU). The study will establish multidimensional models predicting one-year survival and the occurrence of nosocomial infections.
Patients admitted to ICU undergo routine biological sampling. In addition to these, minimal supplementary samples will be collected for immunological and inflammatory biomarker analysis at admission, day 1, day 4, day 8, ICU discharge or day 28, and at 12 months. Additional samples may be taken during clinically significant events (nosocomial infections, complications).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Admission to ICU within 24 hours
Exclusion Criteria:
* Moribund patient (ECOG=4)
* Legal protection (guardianship/curatorship)
* Uninsured patients
* Pre-existing immunosuppression (active/recent cancer, hematologic disease, autoimmune disease, organ transplant, HIV)
* Pregnant or breastfeeding women
* Participation in another interventional trial
* Patients under AME
Primary outcome measure(s)
Overall survival of patients admitted to intensive care. — 12 months Difference in overall survival between ISU patients with different immunological and inflammatory profiles upon completion of the 12-month follow-up period.
Multidimensional flow cytometry leukocyte profiling — Change from baseline to 12 months The isolated cell samples will be analyzed to determine the absolute number and percentage of B cells, monocytes, CD4+ and CD8+ T cells, CD3+CD56+ NKT cells, and NK cells
Inflammatory profile of ICU patients — Change from baseline to 12 months Inflammation-related protein biomarkers will be analyzed using Olink assay
Trial sites (1)
Facility
City
Region
Status
AP-HP Laribosière Hospital, Anesthesia and Critical Care Departement
Paris
France
Recruiting
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
